Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert J Bitterman is Chairman, Pres. & CEO at Phio Pharmaceuticals. OQRO lists 15 transactions filed with the SEC under this name, the latest on Nov 10, 2026, each linked to the official Form 4.
Chairman, Pres. & CEO
Disclosures on record
15
Companies involved
1
8 buys, median −5.8 pts vs S&P 500, beat it 3 of 8 times.
Average −0.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed May 23, 2025 to Jun 29, 2026, measured from the first close after the filing. Past results, not a forecast.
11 purchases disclosed; 38% of the 8 measured at 90 days finished ahead of the index. $1,000 placed after each of the 8 purchases disclosed since 2025-11-14 would be worth $5.8K today ($8K put in); the same in the S&P 500 (SPY): $8.4K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Phio PharmaceuticalsPHIO
15 disclosures · May 2025 – Nov 2026 · 12 bought
Nov 9, 2026Bought~$21Kdisclosed Nov 10
DetailsOfficial recordSep 28, 2026400Kdisclosed Sep 29
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Sep 22, 2026Bought~$2.1Kdisclosed Sep 23
DetailsOfficial recordSep 11, 202669Kdisclosed Sep 15
DetailsOfficial recordAug 18, 2026Bought~$11Kdisclosed Aug 19
DetailsOfficial recordJun 26, 2026Bought~$9.9Kdisclosed Jun 29
DetailsOfficial recordFeb 5, 2026120Kdisclosed Feb 6
DetailsOfficial recordDec 31, 2025Bought~$5.2Kdisclosed Jan 2
DetailsOfficial recordDec 23, 2025Bought~$5.1Kdisclosed Dec 29
DetailsOfficial recordNov 21, 2025Bought~$5.7Kdisclosed Nov 24
DetailsOfficial recordNov 18, 2025Bought~$6.3Kdisclosed Nov 19
DetailsOfficial recordJun 10, 2025Bought~$4.8Kdisclosed Jun 11
DetailsOfficial recordJun 9, 2025Bought~$4.1Kdisclosed Jun 10
DetailsOfficial recordMay 21, 2025Bought~$5.3Kdisclosed May 23
DetailsOfficial recordMay 22, 2025Bought~$2.1Kdisclosed May 23
DetailsOfficial recordAs of the latest filing on , Robert J Bitterman reported holding 789,871 shares of Phio Pharmaceuticals (PHIO), worth about $609K at the last close of $1 (Nov 13, 2026). In the last 12 months, Robert J Bitterman bought $65K in 8 open-market purchases.
Phio Pharmaceuticals's proxy statement reports total compensation of $1.16M for its chief executive for fiscal year 2025, after $387K for 2024. Robert J Bitterman files with the SEC as Chairman, Pres. & CEO of Phio Pharmaceuticals. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Aug 14, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Phio Pharmaceuticals PHIO | 789,871 | 790K direct | $1 | $609K | Nov 9, 2026 |
Is this Robert J Bitterman’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Robert J Bitterman bought shares on the open market in 7 different years since 2013.
Robert J Bitterman reported 31 open-market purchases and 0 sales since 2013; purchases in 7 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $43K4×4 trades | — |
| 2025 | $39K8×8 trades | — |
| 2024 | $3.8K3×3 trades | — |
| 2023 | $5.7K2×2 trades | — |
| 2022 | $5.3K6×6 trades | — |
| 2015 | $6K2×2 trades | — |
| 2013 | $6K6×6 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 9, 2026, Robert J Bitterman reported holding 789,871 shares of Phio Pharmaceuticals (PHIO). At the last close of $1 on Nov 13, 2026, that is about $609K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Robert J Bitterman reported 8 open-market purchases worth $65K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Phio Pharmaceuticals's proxy statement reports total compensation of $1.16M for its chief executive for fiscal year 2025, after $387K for 2024. Robert J Bitterman files with the SEC as Chairman, Pres. & CEO of Phio Pharmaceuticals. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Robert J Bitterman bought shares on the open market in 7 different years since 2013.
In SEC filings since 2013: the latest open-market purchase is from 2026; no open-market sale is on record.
Phio Pharmaceuticals (PHIO), from 2013 to 2026: 31 purchases and 0 sales.
Robert J Bitterman reported 31 open-market purchases and 0 sales here, 2013 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.